
In 2021, when work began on legislation pertaining to the insulin prices in the US, Novo Nordisk and US-based Eli Lilly intensified their lobbying efforts, as reported by media Stat.
According to the media, legislators started drawing up plans for a ceiling for how much individual patients could be required to pay for their insulin out of pocket.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app